Prevalence of and risk factors for levofloxacin-resistant E. coli isolated from outpatients with urinary tract infection

Korean Journal of Urology

Volumn 52, Issue 8, 2011, Pages 554-559

  Jang, Woo Hyuk ^a   Yoo, Dong Hoon ^b   Park, Seong Woon ^a  

^a Gwangju Christian Hospital   (South Korea)

^b Chonnam National University Medical School   (South Korea)

Author keywords

Drug resistance; Fluoroquinolones; Risk factors

Indexed keywords

AMIKACIN; AMPICILLIN; AZTREONAM; CEFAZOLIN; CEFEPIME; CEFOTAXIME; CEFOTETAN; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; SULFAMETHOXAZOLE; SULTAMICILLIN; TIMENTIN; TOBRAMYCIN; TRIMETHOPRIM;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; FEMALE; HUMAN; LEVOFLOXACIN RESISTANT ESCHERICHIA COLI; MAJOR CLINICAL STUDY; MALE; NEUROGENIC BLADDER; OUTPATIENT; PRESCHOOL CHILD; RETROSPECTIVE STUDY; RISK FACTOR; SCHOOL CHILD; URINALYSIS; URINARY TRACT INFECTION; URINE CULTURE; UROLITHIASIS;

EID: 80052042309     PISSN: 20056737     EISSN: 20056745     Source Type: Journal    
DOI: 10.4111/kju.2011.52.8.554     Document Type: Article

References (23)

1. Health IMS. Midas database. Korea: IMS Health; 2010 4Q.
2. Iravani A, Richard GA. Treatment of urinary tract infections with a combination of amoxicillin and clavulanic acid. Antimicrob Agents Chemother 1982;22:672-7.
3. Lee H, Kim CK, Lee J, Lee SH, Ahn JY, Hong SG, et al. Antimicrobial resistance of clinically important bacteria isolated from 12 hospitals in Korea in 2005 and 2006. Korean J Clin Microbiol 2007;10:59-69.
4. Tenover FC. Mechanisms of antimicrobial resistance in bacteria. Am J Infect Control 2006;34(5 Suppl 1):S3-10.
5. Lee SJ, Cho YH, Kim BW, Lee JG, Jung SI, Lee SD, et al. A multicenter Study of antimicrobial susceptibility of uropathogens causing acute uncomplicated cystitis in woman. Korean J Urol 2003;44:697-701.
6. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis 1999;29:745-58.
7. Friedland I, Stinson L, Ikaiddi M, Harm S, Woods GL. Resistance in Enterobacteriaceae: results of a multicenter surveillance study, 1995-2000. Infect Control Hosp Epidemiol 2003;24: 607-12.
8. Croom KF, Goa KL. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs 2003;63:2769-802.
9. Moreira ED Jr, DE Siqueira IC, Alcantara AP, Guereiro DE Moura CG, DE Carvalho WA, Riley L. Antimicrobial resistance of Escherichia coli strains causing community-acquired urinary tract infections among insured and uninsured populations in a large urban center. J Chemother 2006;18:255-60.
10. Zervos MJ, Hershberger E, Nicolau DP, Ritchie DJ, Blackner LK, Coyle EA, et al. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. Clin Infect Dis 2003;37:1643-8.
11. Mutnick AH, Rhomberg PR, Sader HS, Jones RN. Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001). J Antimicrob Chemother 2004;53:290-6.
12. Ko HS, Choi DY, Han YT. A study of the changes of antibiotic sensitivity to the causative organisms of urinary tract infection for recent 5 years. Korean J Urol 1999;40:809-16.
13. Song HJ, Kim SJ. A study of antimicrobial sensitivity to the causative organism of urinary tract infection. Korean J Urol 2005; 46:68-73.
14. Ryu KH, Kim MK, Jeong YB. A recent study on the antimicrobial sensitivity of the organisms that cause urinary tract infection. Korean J Urol 2007;48:638-45.
15. Ernst ME, Ernst EJ, Klepser ME. Levofloxacin and trovafloxacin: the next generation of fluoroquinolones? Am J Health Syst Pharm 1997;54:2569-84.
16. Davis R, Bryson HM. Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 1994;47:677-700.
17. Li Y, Huang X, Yao L, Shi R, Zhang G. Advantages of moxifloxacin and levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis. Wien Klin Wochenschr 2010;122:413-22.
18. Wispelwey B, Schafer KR. Fluoroquinolones in the management of community-acquired pneumonia in primary care. Expert Rev Anti Infect Ther 2010;8:1259-71.
19. Weinrich M, Scheingraber S, Stremovskaia T, Schilling MK, Kees F, Pistorius GA. Liver tissue concentrations of levofloxacin after single intravenous administration of 500 mg for antibiotic prophylaxis in liver surgery. Int J Antimicrob Agents 2006;28:221-5.
20. Goto T, Makinose S, Ohi Y, Yamauchi D, Kayajima T, Nagayama K, et al. Diffusion of piperacillin, cefotiam, minocycline, amikacin and ofloxacin into the prostate. Int J Urol 1998;5:243-6.
21. Nickel JC, Downey J, Clark J, Casey RW, Pommerville PJ, Barkin J, et al. Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo-controlled multicenter trial. Urology 2003;62:614-7.
22. Johnson L, Sabel A, Burman WJ, Everhart RM, Rome M, MacKenzie TD, et al. Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates. Am J Med 2008; 121:876-84.
23. Miura T, Tanaka K, Shigemura K, Nakano Y, Takenaka A, Fujisawa M. Levofloxacin resistant Escherichia coli sepsis following an ultrasound-guided transrectal prostate biopsy: report of four cases and review of the literature. Int J Urol 2008;15:457-9.